Appointment of Chief Financial Officer Designate

The Board of Genus (LSE: GNS), a leading global animal genetics company, is pleased to announce that it has appointed Andy Russell as Chief Financial Officer ("CFO") and Executive Director, following a comprehensive search process.

Andy will commence with Genus and join the Board on 1st August 2025, taking over from Alison Henriksen after she retires from the Company on 31st July 2025, after more than five years in the role.

Andy is an experienced CFO, who will join Genus after nearly 12 years with global medical device manufacturer Smith & Nephew plc. He currently serves as Senior Vice President, Group Finance and M&A, operating as deputy to the Group CFO and leading approximately 400 people globally as he oversaw Group reporting, Controllership, FP&A, Tax, Treasury and M&A. This follows a succession of increasingly senior roles within the organisation, including CFO for the Global Orthopedics division, Interim President for EMEA and CFO for EMEA (while also acting as Finance lead for Global M&A and Strategic Projects).

Before joining Smith & Nephew, Andy spent 17 years with KPMG, the last three of them as a Director, Transaction Services in the National Markets Division and the Private Equity Group.

Jorgen Kokke, Chief Executive Officer of Genus, said:

"I am delighted that we have been able to secure an executive of Andy's caliber. His blend of deep finance expertise and strong commercial acumen will help us take Genus through the next stage of its development as we continue to pursue our strategic priorities".

Andy Russell, incoming CFO, said:

"I am excited to be joining a business that has so many growth opportunities to execute against. I look forward to working with Jorgen and the Board to capitalise on these prospects and deliver value to all our stakeholders".

Remuneration

Andy Russell will receive a salary of £430,000. He will receive a pension contribution of 6% of salary as well as other standard core benefits. Andy will be eligible for discretionary variable remuneration. Under the current Directors' Remuneration Policy the annual bonus maximum is 175% of salary and there is potential to be awarded 200% of salary under the Company's Performance Share Plan.

Further details including any buyout (if required) will be disclosed in full in the Company's 2025 Directors' Remuneration Report.

Regulatory Notes This announcement is made in accordance with Listing Rule 6.4.6R. There are no matters to be disclosed in connection with Listing Rule 6.4.8R (1) - (6).